Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

88
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
88
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

87
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
87
Chronopharmacokinetics: Time-Dependent Pharmacokinetics01:20

Chronopharmacokinetics: Time-Dependent Pharmacokinetics

285
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
285
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

215
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
215
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

119
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
119
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

97
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergency Department Management of Perinatal Substance Use Disorder: Discussing Gaps and Opportunities for Resident Education.

Annals of emergency medicine·2026
Same author

An orthotopic vestibular schwannoma mouse model to study tumor-host interactions and mechanism of sensorineural hearing loss.

Journal of neuroscience methods·2026
Same author

Serial Monitoring of the Audiogram in Hearing Conservation using Gaussian Processes.

Frontiers in audiology and otology·2025
Same author

The Direct and Individual Transcriptional Function of the Human Homodimeric and Heterodimeric Basic Helix-Loop-Helix Transcription Factors E47 and Scleraxis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

[Seroprevalence and infection by human parvovirus B19 in pregnant women from Córdoba, Argentina, 2021-2022]

Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)·2024
Same author

Human parvovirus B19 vertical infection and hydrops fetalis. A case report.

Archivos argentinos de pediatria·2024

Related Experiment Video

Updated: Nov 16, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.7K

Changing the time intervals between cisplatin cycles alter its ototoxic side effect.

Eric C Bielefeld1, Alicia Gonzalez1, J Riley DeBacker1

  • 1Department of Speech and Hearing Science, The Ohio State University, 110 Pressey Hall, 1070 Carmack Road, Columbus, OH 43210, USA.

Hearing Research
|February 22, 2021
PubMed
Summary

Increasing cisplatin dosing intervals reduces hearing loss and cochlear damage. Longer breaks between chemotherapy cycles minimize ototoxicity, but further research is needed to optimize timing and efficacy.

Keywords:
CisplatinDosing, Cochlea, Hearing lossOtotoxicity

More Related Videos

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

18.0K
Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice
09:06

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice

Published on: January 9, 2019

14.3K

Related Experiment Videos

Last Updated: Nov 16, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.7K
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

18.0K
Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice
09:06

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice

Published on: January 9, 2019

14.3K

Area of Science:

  • Ototoxicity research
  • Cancer chemotherapy side effects
  • Auditory neuroscience

Background:

  • Cisplatin is a widely used chemotherapy drug.
  • Ototoxicity, or hearing loss, is a common and serious side effect of cisplatin.
  • Current strategies to minimize cisplatin ototoxicity include dose adjustments and early identification of hearing loss.

Purpose of the Study:

  • To investigate the impact of varying inter-cycle intervals of cisplatin administration on ototoxicity.
  • To determine if extending the rest periods between cisplatin cycles can reduce hearing damage.

Main Methods:

  • CBA/CaJ mice received a cumulative dose of 48 mg/kg cisplatin in three cycles.
  • Cycles were separated by 10, 17, or 87 days.
  • Ototoxicity was assessed via auditory brainstem response threshold shifts and quantification of outer hair cell loss.

Main Results:

  • Longer intervals between cisplatin cycles resulted in significantly lower auditory threshold shifts.
  • Increased rest periods between doses led to reduced outer hair cell lesions in the cochlea.
  • The findings suggest a dose-interval relationship in cisplatin-induced ototoxicity.

Conclusions:

  • Increasing the rest intervals between cisplatin cycles is an effective strategy for reducing ototoxicity.
  • Slowing down cisplatin administration by extending inter-cycle breaks can mitigate hearing loss and cochlear damage.
  • Further studies are required to optimize these dosing schedules and evaluate their impact on anti-tumor efficacy.